E 
Eli Lilly and Co LLY · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500
1,354.00
-0.79%
Close of 6 Nov 2026, in USD
At a glance
Figures in USD, from our data supplier.
Revenue
$65.18bn
FY2016FY2025
Net income
$20.64bn
FY2016FY2025
Free cash flow
$8.97bn
FY2016FY2025
Shareholders' equity
$26.54bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18bn | $45.04bn | $34.12bn | $28.54bn | $28.32bn | $24.54bn | $22.32bn | $21.49bn | $19.97bn | $21.22bn |
| Gross profit | $54.62bn | $36.62bn | $27.04bn | $21.91bn | $21.01bn | $19.06bn | $17.60bn | $16.81bn | $15.53bn | $15.51bn |
| Research and development | $13.34bn | $10.99bn | $9.31bn | $7.19bn | $6.93bn | $5.98bn | $5.59bn | $5.05bn | $5.10bn | $5.31bn |
| Operating income | $29.70bn | $17.50bn | $7.04bn | $8.65bn | $7.93bn | $7.54bn | $6.00bn | $6.03bn | $4.25bn | $3.87bn |
| Net income | $20.64bn | $10.59bn | $5.24bn | $6.24bn | $5.58bn | $6.19bn | $8.32bn | $3.23bn | −$204.1m | $2.74bn |
| Diluted earnings per share | 22.98 | 11.73 | 5.80 | 6.57 | 5.85 | 6.47 | 8.69 | 3.06 | -0.19 | 2.49 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $112.48bn | $78.71bn | $64.01bn | $49.49bn | $48.81bn | $46.63bn | $39.29bn | $43.91bn | $44.98bn | $38.81bn |
| Cash and short-term investments | $7.27bn | $3.42bn | $2.93bn | $2.21bn | $3.91bn | $3.68bn | $2.44bn | $7.41bn | $8.03bn | $6.04bn |
| Total liabilities | $85.94bn | $64.44bn | $53.14bn | $38.71bn | $39.65bn | $40.81bn | $36.59bn | $33.00bn | $33.31bn | $24.73bn |
| Debt | $42.50bn | $33.64bn | $25.23bn | $16.24bn | $16.88bn | $16.60bn | $15.32bn | $10.30bn | $13.65bn | $10.31bn |
| Shareholders' equity | $26.54bn | $14.19bn | $10.77bn | $10.65bn | $8.98bn | $5.64bn | $2.61bn | $10.91bn | $11.59bn | $14.01bn |
| Shares outstanding | 898m | 903m | 904m | 950m | 954m | 957m | 958m | 1,057m | 1,052m | 1,101m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $16.81bn | $8.82bn | $4.24bn | $7.08bn | $7.26bn | $6.50bn | $4.84bn | $5.52bn | $5.62bn | $4.85bn |
| Capital spending | −$7.84bn | −$8.40bn | −$7.39bn | −$2.48bn | −$1.87bn | −$2.03bn | −$1.35bn | −$3.02bn | −$2.16bn | −$1.09bn |
| Free cash flow | $8.97bn | $414.3m | −$3.15bn | $4.60bn | $5.39bn | $4.47bn | $3.48bn | $2.51bn | $3.45bn | $3.76bn |
| Dividends paid | −$5.38bn | −$4.68bn | −$4.07bn | −$3.54bn | −$3.09bn | −$2.69bn | −$2.41bn | −$2.31bn | −$2.19bn | −$2.16bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97bn | $19.80bn | $19.29bn | $17.60bn | $15.56bn | $12.73bn | $13.53bn | $11.44bn |
| Gross profit | $19.71bn | $16.22bn | $16.41bn | $14.59bn | $13.11bn | $10.50bn | $11.13bn | $9.27bn |
| Operating income | $8.98bn | $8.85bn | $8.78bn | $8.39bn | $7.13bn | $5.41bn | $5.80bn | $4.55bn |
| Net income | $7.09bn | $7.40bn | $6.64bn | $5.58bn | $5.66bn | $2.76bn | $4.41bn | $970.3m |
| Diluted earnings per share | 7.94 | 8.28 | 7.39 | 6.22 | 6.30 | 3.07 | 4.88 | 1.07 |
| Cash from operations | $10.69bn | $5.33bn | $3.22bn | $8.84bn | $3.09bn | $1.67bn | $2.47bn | $3.71bn |
| Capital spending | −$2.93bn | −$2.33bn | −$2.55bn | −$223.0m | −$1.80bn | −$3.27bn | −$1.75bn | −$4.17bn |
| Free cash flow | $7.76bn | $3.01bn | $678.0m | $8.61bn | $1.28bn | −$1.60bn | $726.0m | −$459.0m |
| Total assets | $142.28bn | $116.58bn | $112.48bn | $114.94bn | $100.92bn | $89.39bn | $78.71bn | $75.61bn |
| Cash and short-term investments | $8.95bn | $5.28bn | $7.27bn | $9.91bn | $3.55bn | $3.22bn | $3.42bn | $3.52bn |
| Debt | $54.91bn | $43.37bn | $42.50bn | $42.51bn | $39.90bn | $38.52bn | $33.64bn | $31.12bn |
| Shareholders' equity | $33.88bn | $31.20bn | $26.54bn | $23.79bn | $18.27bn | $15.76bn | $14.19bn | $14.24bn |
Financial ratios
Data as of 30 Aug 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% |
| Operating margin | 40.5% | 38.9% | 20.6% | 30.3% | 28.0% | 30.7% |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% |
| Return on equity | 77.8% | 74.6% | 48.6% | 58.6% | 62.2% | 109.8% |
| Return on assets | 18.3% | 13.5% | 8.2% | 12.6% | 11.4% | 13.3% |
| Free cash flow yield | 2.3% | 1.6% | 1.1% | 0.9% | 0.8% | 0.8% |
| Revenue growth | 44.7% | 32.0% | 19.6% | 0.8% | 15.4% | 9.9% |
| Earnings growth | 94.9% | 102.1% | -16.1% | 11.9% | -9.9% | -25.5% |
| Current ratio | 1.58x | 1.15x | 0.94x | 1.05x | 1.23x | 1.40x |
| Debt to equity | 1.60x | 2.37x | 2.34x | 1.52x | 1.88x | 2.94x |
| Equity ratio | 23.6% | 18.0% | 16.8% | 21.5% | 18.4% | 12.1% |
| Interest coverage | 33.16x | 22.42x | 14.49x | 26.10x | 23.35x | 20.96x |
| R&D as a share of sales | 20.5% | 24.4% | 27.3% | 25.2% | 24.5% | 24.4% |
| Buybacks as a share of market value | 0.6% | 0.1% | 4.9% | 0.4% | 0.3% | 0.1% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 31.7% | 21.6% | 12.6% |
| Operating income | 50.8% | 31.6% | 23.5% |
| Net income | 49.0% | 27.2% | 24.0% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 82.8% | 81.1% | 79.8% | 78.8% |
| Operating margin | 42.8% | 36.4% | 34.7% | 30.9% |
| Net margin | 28.3% | 24.7% | 24.1% | 21.5% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 46.8 | 65.8 | 100.5 | 55.7 | 47.2 | 26.1 | 15.1 | 37.9 | -435.3 | 29.6 |
| Price to sales | 14.8 | 15.5 | 15.4 | 12.2 | 9.3 | 6.6 | 5.6 | 5.7 | 4.5 | 3.8 |
Market value over time
30 Sept 2016 to 28 Aug 2026, in USD
$85.16bn$1.05trn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 38% | 32% | 62% | 36% | 56% | 27% | 21% | 27% | 17% | -11% |
Dividends and splits
Per share, in the currency the company pays
Paid for 36 years. Last went ex-dividend on 14 Aug 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 3.46 | 6.23 | 5.40 | 4.69 | 4.07 | 3.53 | 3.07 | 2.675 |
- 2-for-1 split · 16 Oct 1997
- 2-for-1 split · 21 Dec 1995
- 2-for-1 split · 1 May 1989
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.